Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7010905 | 0.84 | USP2 (0.46) | CRBNDDB1USP2SMN1; SMN2KDM4E | |
| SCHEMBL15447211 | 0.78 | DDB1 (0.47) | CRBNDDB1USP2SMN1; SMN2KDM4E | |
| SCHEMBL769732 | 0.78 | USP2 (0.46) | CRBNDDB1USP2SMN1; SMN2KDM4E | |
| SCHEMBL12501315 | 0.77 | USP2 (0.47) | CRBNDDB1USP2SMN1; SMN2KDM4E | |
| SCHEMBL17101524 | 0.77 | DDB1 (0.33) | CRBNDDB1 | |
| SCHEMBL2028457 | 0.76 | DDB1 (0.45) | CRBNDDB1USP2SMN1; SMN2KDM4E | |
| SCHEMBL14335247 | 0.76 | USP2 (0.42) | CRBNDDB1USP2SMN1; SMN2KDM4E | |
| SCHEMBL4267194 | 0.75 | CRBN (0.46) | CRBNDDB1USP2SMN1; SMN2KDM4E | |
| SCHEMBL15798840 | 0.75 | USP2 (0.50) | CRBNDDB1USP2SMN1; SMN2KDM4E | |
| SCHEMBL17608975 | 0.75 | CRBN (0.42) | CRBNDDB1USP2SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202843-B2 | Muscarinic receptor agonists | NXERA PHARMA UK LIMITED (GB) | 2025-01-21 | — | — | US | disclosed |
| CN-110903306-B | Muscarinic receptor agonists | 赫普泰雅治疗有限公司 | 2022-09-23 | — | — | CN | disclosed |
| US-20220048928-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
| US-20220048928-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
| US-11034704-B2 | Muscarinic receptor agonists | NXERA PHARMA UK LIMITED (GB) | 2021-06-15 | — | — | US | disclosed |
| US-11034704-B2 | Muscarinic receptor agonists | NXERA PHARMA UK LIMITED (GB) | 2021-06-15 | — | — | US | disclosed |
| EP-3119396-B1 | MUSCARINIC RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2021-05-05 | — | — | EP | disclosed |
| EP-3119396-B1 | MUSCARINIC RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2021-05-05 | — | — | EP | disclosed |
| EP-3271358-B1 | SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LTD (GB) | 2020-11-18 | — | — | EP | disclosed |
| CN-110903306-A | Muscarinic receptor agonists | 赫普泰雅治疗有限公司 | 2020-03-24 | — | — | CN | disclosed |
| US-7402590-B2 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-7351707-B2 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20080051429-A1 | USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS | ACADIA PHARMACEUTICALS INC. | 2008-02-28 | — | — | US | disclosed |
| US-20070161621-A1 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | ACADIA PHARMACEUTICALS (US) | 2007-07-12 | — | — | US | disclosed |
| US-7217719-B2 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20060205710-A1 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060199794-A1 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. | 2006-09-07 | — | — | US | disclosed |
| US-20050256108-A1 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. | 2005-11-17 | — | — | US | disclosed |
| US-6911452-B2 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. (US) | 2005-06-28 | — | — | US | disclosed |
| US-20030166928-A1 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256108-A1 | Spiroazacyclic compounds as monoamine receptor modulators | MAOA, MAOB, HTR5A | CRBN 4179/4885DDB1 4575/4885USP2 3888/4885 |
| US-20220048928-A1 | MUSCARINIC RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | CRBN 3770/4885DDB1 4415/4885USP2 3684/4885 |
| US-20060205710-A1 | Spiroazacyclic compounds as monoamine receptor modulators | MAOA, MAOB, HTR5A | CRBN 4179/4885DDB1 4575/4885USP2 3888/4885 |
| US-12202843-B2 | Muscarinic receptor agonists | CHRM1, CHRM2, CHRM3 | CRBN 3770/4885DDB1 4415/4885USP2 3684/4885 |
| US-20030166928-A1 | Spiroazacyclic compounds as monoamine receptor modulators | MAOA, MAOB, HTR5A | CRBN 4179/4885DDB1 4575/4885USP2 3888/4885 |
| US-20080051429-A1 | USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS | HTR4, HTR3B, HTR2A | CRBN 3846/4885DDB1 4027/4885USP2 3678/4885 |
| US-20070161621-A1 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | MAOA, MAOB, HTR5A | CRBN 4179/4885DDB1 4575/4885USP2 3888/4885 |
| US-20060199794-A1 | Spiroazacyclic compounds as monoamine receptor modulators | MAOA, MAOB, HTR5A | CRBN 4179/4885DDB1 4575/4885USP2 3888/4885 |
| US-11034704-B2 | Muscarinic receptor agonists | CHRM1, CHRM2, CHRM3 | CRBN 3770/4885DDB1 4415/4885USP2 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.